RYTM Q3 2023 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M+425.3% YoY

Gross Profit

$20M89.3% margin

Operating Income

-$44M-195.3% margin

Net Income

-$44M-196.2% margin

EPS (Diluted)

$-0.76

QoQ Revenue Growth

+17.1%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$354M

Total Liabilities

$157M

Stockholders' Equity

$197M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$4M	+425.3%
Gross Profit	$20M	$4M	+430.6%
Operating Income	-$44M	-$39M	-11.9%
Net Income	-$44M	-$41M	-8.1%

Revenue Segments

Product revenue

$23M100%